In PepBank now:147 peptides, 6 blends and 13 other compounds97,577 study results from 17,383 studies8,473 clinical trialsUpdated
Comparing 2 peptides · Data version 308560
Swipe sideways to see every peptide.
| Peptide | Conjugate ACE-031 (ramatercept) | Natural peptide Thymosin beta-4 (human) | |
|---|---|---|---|
| Identity | |||
| Kind | Conjugate | Natural peptide | |
| Area | Recovery and repair | Recovery and repair | |
| Evidence | |||
| Amount of evidence | 34 | 1,449 (plus 953 on natural levels, listed separately) | |
| Evidence level | Has results from studies in people | Has results from studies in people | |
| Safety | |||
| Safety results | 5 (5 in people) | 12 (8 in people) | |
| Status | |||
| Approval | |||
| Sport (WADA) | |||
| Registered trials | 4 | 13 · 1 active2 more mention it but do not test it | |
Shared outcomes
From the regulatory data of each peptide.
Its most advanced trial is in phase 2. The FDA, the EMA and the other sources we use show no approval (as of 21 Oct 2026).
Its most advanced trial is in phase 3. The FDA, the EMA and the other sources we use show no approval (as of 8 Oct 2026).
Outcome groups with study results for at least two of these peptides. Counts include only results from studies that gave the peptide. Bar length is the number of results, on one scale. The bars show how much was studied, not how large an effect was. A peptide with more studies can look stronger here without being stronger. For results, see the randomized results above.
| Outcome group | ACE-031 (ramatercept) | Thymosin beta-4 (human) |
|---|---|---|
| Bone and jointWhole body | 22 | 531142 |
| PharmacokineticsPharmacology |
PepBank is a research reference. Talk to a doctor before you use any peptide.
33
287183 |
| Adverse eventsWhole body | 55 | 981 |
|---|
| Muscle injury and repairMusculoskeletal | 21318 | 734 |
|---|
| Body weightMetabolic and weight | 211 | 33 |
|---|
| Exercise and physical functionMusculoskeletal | 11 | 11 |
|---|
For each outcome that two or more peptides have results for: the best result of a single randomized trial, on the same measure (the same kind of number, the same unit). When a trial has several dose arms, the cell shows the highest dose arm. The trials differ in people, length and dose, so a gap between two cells is not proof that one peptide works better.
No outcome has a randomized-trial result on the same measure for two or more of these peptides yet.
Registered trials, ranked by phase (late phases first), then posted results and enrollment. Status is the registry status. Study results come from published studies. Results posted at ClinicalTrials.gov are shown on each trial page.
Top 3 of 4 trials, ranked by phase, then posted results and enrollment: 1 completed · 2 stopped early · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA24 participantsApr 2010 to Jun 2011
Duchenne Muscular Dystrophy
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA11 participantsOct 2010 to May 2011
Duchenne Muscular Dystrophy
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA70 participantsAug 2009 to Feb 2011
Muscular Atrophy
Top 3 of 13 trials, ranked by phase, then posted results and enrollment: 2 completed · 1 stopped early · 3 with posted results · source ClinicalTrials.gov (opens in a new tab)
ReGenTree, LLC700 participants24 May 2019 to 7 Oct 2021
Dry Eye Syndromes · Dry Eye
ReGenTree, LLC601 participantsNov 2016 to Mar 2018
Dry Eye Syndrome
ReGenTree, LLC18 participants17 Sept 2015 to 9 Mar 2020
Neurotrophic Keratopathy
2 more mention it but do not test it. They only measure it or name it in their text.